A nationwide recall of compounded GLP-1 injections is raising new safety concerns about one of the most popular methods people are using to shed pounds. According to the Food and Drug Administration (FDA), Apothecary Pharma LLC has voluntarily recalled certain compounded tirzepatide injections over a “lack of assurance of sterility.” The medication contains the same active ingredient used in Mounjaro and Zepbound, but the recalled products were manufactured by a separate compounding pharmacy.
The weight loss shot recall began September 24, 2026, and was classified as a “Class II” recall on October 8. The FDA defines that classification as a situation in which using an affected product could cause “temporary or medically reversible adverse health consequences” or where the likelihood of serious harm is remote.
The agency has not confirmed that the recalled injections are contaminated. However, the inability to guarantee sterility raises concerns because the medication is injected directly into the body.
The recall specifically involves Apothecary Pharma’s compounded tirzepatide, not the FDA-approved versions sold as Mounjaro or Zepbound.
What makes the situation especially concerning is that the North Carolina pharmacy had already received a federal warning about its manufacturing practices.
In December 2025, the FDA issued Apothecary Pharma a warning letter documenting “serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.”
The letter followed a May 2025 inspection of the company’s Cary, North Carolina facility.
According to federal inspectors, employees were observed handling sterile medications in ways that could compromise cleanliness, including placing gloved hands over exposed containers, failing to sanitize gloves between activities, and exposing skin in sterile production areas.
The FDA also documented visibly rusty equipment, inadequate airflow testing and problems with cleaning procedures. Investigators identified deficiencies in product labeling and adverse event reporting procedures involving compounded tirzepatide and semaglutide.
Although Apothecary Pharma submitted corrective actions, the FDA said several responses were inadequate or lacked sufficient supporting evidence.
The new GLP-1 recall involves tirzepatide injections containing 18 milligrams per milliliter, packaged in 4 milliliter sterile multidose vials.
According to the FDA recall information reproduced by telehealth provider Fifty 410, the affected October lot numbers and beyond use dates are:
AP-202622 (October 7), AP-202623 (October 8), AP-202624 (October 19), AP-202625 (October 20), AP-202627 (October 26), AP-202628 (October 27), AP-202629 (October 28) and AP-202630 (October 31).
The affected November lots are:
AP-202631 (November 1), AP-202632 (November 3), AP-202633 (November 7), AP-202634 (November 8), AP-202635 (November 16), AP-202636 (November 17), AP-202637 (November 18), AP-202638 (November 19), AP-202639 (November 20), AP-202640 (November 21), AP-202641 (November 22), AP-202642 (November 24), AP-202643 (November 25) and AP-202644 (November 26).
All dates are in 2026.
The FDA enforcement information reports 22 recalled vials, but the accompanying records identify 22 separate lot numbers. USA TODAY reported that it requested clarification from the agency about whether the figure represents individual vials or entire production lots.
Questions have also emerged about whether patients should continue using the affected injections.
NewLife Rx, a pharmacy fulfillment service that distributed some of the medication, told customers that the recall involved documentation and manufacturing process concerns rather than an identified problem with specific doses.
According to a notice reviewed by USA TODAY, the recall was at the “retail level, which does not extend to patients or require them to stop using or return their medications.”
A statement from NewLife Rx published by Fifty 410 on October 19 also said the compounding pharmacy had advised that no specific medication safety issues had been identified.
However, the FDA’s stated recall reason remains a lack of sterility assurance. Patients with matching lot numbers should speak with their prescriber or dispensing pharmacy before using another dose, rather than assuming the medication is safe based on the recall classification.
The situation comes as GLP-1 medications continue to reshape weight loss treatment across the country.
A November 2025 KFF Health Tracking Poll found that 12% of American adults reported currently taking a GLP-1 medication for weight loss, diabetes, or another health condition. Nearly 18% said they had used one at some point.
While FDA-approved drugs undergo clinical testing and regulatory review, compounded versions do not receive the same approval for safety, effectiveness, and quality.
Compounding pharmacies can legally prepare customized medications for patients with specific medical needs, but they must comply with applicable federal and state requirements.
The FDA has intensified its scrutiny of compounded GLP-1 injections as reports of medication errors and adverse events have accumulated.
As of May 31, 2026, federal regulators had received 990 adverse event reports associated with compounded semaglutide and more than 730 involving compounded tirzepatide.
The FDA cautions that these reports do not establish that the medications directly caused every reported reaction. The figures also do not represent illnesses linked specifically to Apothecary Pharma’s recall.
Among the broader concerns are incorrect dosages, improper storage, questionable ingredients, and errors involving patients measuring injections themselves.
According to an FDA safety alert, some patients using compounded semaglutide have required hospitalization after taking incorrect doses. Reported complications included severe gastrointestinal symptoms, dehydration, fainting, and acute pancreatitis.
Federal oversight has also tightened since the shortages that originally helped drive demand for compounded alternatives.
The FDA determined that the national tirzepatide shortage had ended in December 2024 and that the semaglutide injection shortage had ended in February 2025.
Those decisions restricted the circumstances under which pharmacies and outsourcing facilities could continue producing medications that were essentially copies of commercially available products.
In April 2026, the FDA proposed additional restrictions that would exclude semaglutide, tirzepatide and liraglutide from a list of bulk drug substances available for certain outsourcing facility compounding activities.
The proposal reflected the agency’s position that it had not identified sufficient clinical need for outsourcing facilities to produce those medications from bulk ingredients under that regulatory pathway. The proposal was not itself a blanket ban on all lawful customized prescriptions.
For people purchasing weight loss injections through online providers, the current recall presents another concern: patients may recognize the medication they ordered without knowing which pharmacy actually manufactured it.
The FDA recommends obtaining prescription medications from licensed pharmacies and checking the manufacturer, concentration, lot number, and expiration or beyond-use information on the packaging.
Patients whose medication matches the Apothecary Pharma recall should contact their pharmacist or prescribing clinician for instructions about continued treatment, replacement medication, and safe handling of the affected vial.
